Royal College of Physicians

Royal College of Physicians
11 St Andrews Place
Regent's Park
London NW1 4LE
Tel: +44 (0)20 3075 1560

www.rcplondon.ac.uk

From The Registrar
[redacted] MD FRCP

Meindert Boysen
Programme Director, Centre for Health Technology Evaluation
NICE
TACommB@nice.org.uk

7 November 2013

Dear Mr Boysen

Re: Enzalutamide for the treatment of metastatic hormone relapsed prostate cancer previously treated with a docetaxel-containing regimen [ID600] – Appraisal Consultation Document (ACD)

The Royal College of Physicians (RCP) plays a leading role in the delivery of high quality patient care by setting standards of medical practice and promoting clinical excellence. We provide physicians in the United Kingdom and overseas with education, training and support throughout their careers. As an independent body representing over 29,000 Fellows and Members worldwide, we advise and work with government, the public, patients and other professions to improve health and healthcare.

I write on behalf of the NCRI/RCP/RCR/ACP/JCCO with regard to the above ACD. We are grateful for the opportunity to respond and wish to submit the following joint comments.

Our experts welcome the potential approval for Enzalutamide in the postdocetaxel treatment setting in mCRPC. The ACD specifies that this approval is post a single line of docetaxel chemotherapy only and whilst the number of patients receiving more than 1 line of chemotherapy is small it would have been a great help if the committee had also approved Enzalutamide for patients who have had more than 1 line of chemotherapy. The patient population in the AFFIRM trial included those who had 1 or more lines of chemotherapy.

In reviewing the ACD, it appears that patients in mCRPC setting post one line of docetaxel chemotherapy will potentially be able to avail of both abiraterone and enzalutamide (this is different from the situation with CDF in England where patients who have had abiraterone cannot get Enzalutamide). This increases the number of treatment options for this group of patients.

Yours sincerely

[redacted]
Registrar